T Ruff - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

T Ruff

Showing results (111-120 of 224) with videos related to

Pageof 23

Sort By:

Circulation Journal : Official Journal of the Japanese Circulation Society|February 19, 2016

Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation　- An ENGAGE AF-TIMI 48 SubanalysisTakeshi Yamashita, Yukihiro Koretsune, Yuejin Yang, et al.

European Journal of Heart Failure|June 29, 2016

Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48Giulia Magnani, Robert P Giugliano, Christian T Ruff, et al.

The American Journal of Medicine|March 21, 2016

Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 TrialRobert P Giugliano, Christian T Ruff, Stephen D Wiviott, et al.

European Heart Journal|April 28, 2025

ApoB-containing lipoproteins: count, type, size, and risk of coronary artery diseaseJakub Morze, Giorgio E M Melloni, Clemens Wittenbecher, et al.

American Heart Journal|October 12, 2010

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)Christian T Ruff, Robert P Giugliano, Elliott M Antman, et al.

European Heart Journal. Acute Cardiovascular Care|July 25, 2018

Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48Thomas A Zelniker, Christian T Ruff, Stephen D Wiviott, et al.

American Heart Journal|January 6, 2022

Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroupsBaris Gencer, Alon Eisen, David Berger, et al.

Circulation. Cardiovascular Quality and Outcomes|May 12, 2018

Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction)James Aisenberg, Prapti Chatterjee-Murphy, Kathryn Friedman Flack, et al.

International Journal of Cardiology|February 4, 2020

Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trialAnna Plitt, Christian T Ruff, Assen Goudev, et al.

Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|November 22, 2018

Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trialJan Steffel, Christian T Ruff, Eugene Braunwald, et al.

Pageof 23

Search research articles

Showing results (111-120 of 224) with videos related to

Sort By:

Pageof 23

Circulation Journal : Official Journal of the Japanese Circulation Society|February 19, 2016

Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation　- An ENGAGE AF-TIMI 48 SubanalysisTakeshi Yamashita, Yukihiro Koretsune, Yuejin Yang, et al.

European Journal of Heart Failure|June 29, 2016

The American Journal of Medicine|March 21, 2016

Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 TrialRobert P Giugliano, Christian T Ruff, Stephen D Wiviott, et al.

European Heart Journal|April 28, 2025

ApoB-containing lipoproteins: count, type, size, and risk of coronary artery diseaseJakub Morze, Giorgio E M Melloni, Clemens Wittenbecher, et al.

American Heart Journal|October 12, 2010

European Heart Journal. Acute Cardiovascular Care|July 25, 2018

Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48Thomas A Zelniker, Christian T Ruff, Stephen D Wiviott, et al.

American Heart Journal|January 6, 2022

Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroupsBaris Gencer, Alon Eisen, David Berger, et al.

Circulation. Cardiovascular Quality and Outcomes|May 12, 2018

International Journal of Cardiology|February 4, 2020

Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trialAnna Plitt, Christian T Ruff, Assen Goudev, et al.

Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trialJan Steffel, Christian T Ruff, Eugene Braunwald, et al.

Pageof 23